

Public Declaration of Interests and Confidentiality Undertaking of European Medicines Agency (EMA)

SCIENTIFIC COMMITTEE MEMBERS AND EXPERTS

I, Fernando Cabanas

Organisation/Company:

Country:

Declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

1.1 Employment

No interest declared

1.2 Consultancy

No interest declared

1.3 Strategic advisory role

No interest declared

1.4 Financial interests

No interest declared

1.5 Principal investigator

No interest declared

1.6 Investigator

Time Period	Start Date	End Date	Name of pharmaceutical company	Product Name	Therapeutic indication
Current	01-09-2019	22-03-2023	MedImmune_Astra_Zeneca	MEDI8897_ NIRSEVIMAB. Melody and Medley	Infection Respiratoy Syncytial Virus (RS)
Past	01-12-2021	01-10-2022	JANSSEN Research & Development, LLC and Janssen Cilag, S.A.	JNJ_53718678 (rilematovir) EudraCT NUMBE	Infection Respiratory Syncytial Virus (R)
Current	01-12-2021	22-03-2023	MERCK SHARP & DHOME (MSD)	MK_1654. IND 130097. EudraCT 2020_00	Infection Respiratory Syncytial Virus (R)

1.7 Grant / Funding to organisation /institution

No interest declared

1.8 Close family member interest

No interest declared

1.9 Repurposing of a medicinal product

No interest declared

1.10 Any other interests or facts

_ Prophylactic treatment of the ductus arteriosus in preterm infants by acetaminophen. TRECOPA trial. EudraCT NO. 2019_004297_26. c4c Trial (Academic trial) Current _ALBINO_ Effect of Allopurinol in addition to hypothermia for Hypoxic ischemic brain injury on neurocognitive outcome (ALBINO trial) . EU H 2020_PHC_182015_667224. Code EudraCt: 2016_000222_19. Academic Trial. Current _ PI in La Paz University Hospital and Board member of NeoCirculation Clinical Trials, supported by European Union 7FP. Dobutamine for NEOnatal CIRculatory failure defined by novel biomarkers (NEO_CIRC) UE FP7_ HEALTH_2011_single_stage. EudraCT NeoCirc001:2013_002845_12 PAST _ Randomised controlled clinical trial of standard versus echocardiographically guided ibuprofen treatment for patent ductus arteriosus in preterm infants: a pilot study. J Matern Fetal Neonatal Med. 2013 PAST _ Phase 1 study of two inodilators in neonates undergoing cardiovascular surgery. Pediatr Res. 2013 PAST _ Member of Biomedical Research Foundation Ethic Committee. La Paz University Hospital_IDIPAZ

1.11 Committee for Advanced Therapies (CAT) member or alternate

Not a CAT member or alternate

2.1 Employment

No interest declared

2.2 Consultancy

No interest declared

2.3 Strategic advisory role

No interest declared

2.4 Financial interests

No interest declared

2.5 Principal investigator

No interest declared

2.6 Investigator

No interest declared

2.7 Grant / Funding to organisation /institution

No interest declared

2.8 Close family member interest

No interest declared

2.9 Any other interests or facts

No interest declared

CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality as long as the information or document has not been made public/is not in the public domain.

- Not to disclose (or authorise any other person to disclose) in any way to any third party ¹ any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.
- When expressing views to indicate clearly that the views are my own if acting in my own capacity or those of the EMA, Management Board, Committee, Working Party, Expert Group or other group if acting on behalf of that group.
- Not to disclose any commercially confidential information.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate and complete to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

1. Third party does not include employees of the National Competent Authorities who either have employment contracts that provide confidentiality obligations or are encompassed by confidentiality obligations under national legislation on professional secrecy.

Full Name:	Fernando Cabanas
Date:	2023-03-22

For definitions of activities etc, refer to the policy on handling of competing interests.